about
sameAs
Parkinson’s disease psychosis 2010: A review articleMelperone is ineffective in treating Parkinson's disease psychosisMotor phenotype of LRRK2 G2019S carriers in early-onset Parkinson diseaseClassification and treatment of tardive syndromes.Reduction of freezing of gait in Parkinson's disease by repetitive robot-assisted treadmill training: a pilot study.Pimavanserin for the treatment of Parkinson's disease psychosis.REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3).Scales to assess psychosis in Parkinson's disease: Critique and recommendations.Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelinesAtypical antipsychotics in Parkinson-sensitive populations.The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD studyTreatment of psychosis in Parkinson's disease: safety considerations.Parkinsonism in a nursing home: underrecognition.Sleep and fatigue in Parkinson's disease.Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.Non-motor aspects of Parkinson's disease.Fatigue in Parkinson's disease: a review.The management of psychosis in movement disorder patients.Management of the behavioral aspects of Parkinson's disease.Parkinson's disease-related fatigue: A case definition and recommendations for clinical research.Visual hallucinations in photographs in Parkinson's diseaseFatigue in Parkinson's disease: report from a mutidisciplinary symposium.Sleep disturbances and Parkinson's disease.Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers.Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.Current use of clozapine in Parkinson disease and related disorders.Neuropsychiatric symptoms in an inpatient Parkinson's disease sample.Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease.Managing idiopathic Parkinson's disease in patients with schizophrenic disorders.Fatigue in Parkinson's disease.Atypical antipsychotic drugs in the treatment of Parkinson's disease.The glabellar reflex is a poor measure of Parkinson motor severity.Treating psychosis in movement disorder patients: a review.A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials.Phenomenology of dreams in Parkinson's disease.
P50
Q22251238-5CEA6737-AD78-4F89-A6E0-409C444640E2Q28260569-7CFF158F-4A94-4529-862D-0574F1976879Q33723751-CB87B25C-D900-45E8-BCA2-D17D69FF3EB1Q34205009-666200BF-FA54-4D4C-A9D5-94E2363AB0B4Q34273806-622FB382-8A22-40D9-85A6-A638715CDF0EQ34369646-41E869DE-2588-43BD-BA2E-5EDF439D2426Q34543915-20AD7658-28BF-48AE-AD68-94E3A986D752Q34586737-965F820E-B3BB-43C9-B4E9-AEB17601CA03Q34658560-FCA67187-0DC1-4511-BF47-FC6C20BD9F06Q34660675-C26AC5E2-7225-4B50-99A9-5F6C494788D0Q34758986-CB1327AB-EC09-4002-9132-509757929D7BQ34851726-1A997E93-FA0E-46F5-B96A-E38F7A98D042Q35054613-C1F10E08-F30A-44E4-92AB-67758BCC1FF4Q35157477-78E2004A-22D2-451E-9BD1-FCE906EDF829Q35690183-46577214-2682-488D-B00D-2B9E8F7F1335Q35756465-663BBD5C-6456-4318-81A1-4FF1B6D803C6Q35897974-0A12E5C2-2B5E-4E45-BE1B-77B4CC51AB49Q35898027-4FDFBCD2-8E3B-4157-A8D0-F10842B406F8Q36005602-B0F7FF80-37DA-4781-9249-CFD6F099711CQ36525764-C89ABEDC-0BCF-4CE0-A92C-7AEAF11B8668Q36667874-0AB91D7A-B7B4-493E-BC6E-94F8C3260CD6Q36808034-742501FE-F9C9-4573-816D-8EB093BE606EQ36847271-11F8556A-855E-440B-AE51-2C39BA43C874Q36890229-470AB4F7-8AB0-4CDE-82BC-D75EEC5309E4Q36893914-08D21377-DF04-44BC-98FB-0AFF2163F675Q36943866-794739B4-ADAF-483C-AA99-0F677B36D311Q37103579-FFF3487F-B897-4B2E-B595-91E5B633E207Q37494297-B957F249-1C20-49D9-A225-DA03DB63C71DQ37625797-F51FA19D-BE47-434A-87C5-297BCF8A4AD5Q37659762-81FDB8FF-EB81-4FA0-8B13-8420831E5AA8Q37679712-CD86C253-973D-40BF-9A41-97E219D94D19Q37749714-FDA384C7-595D-4F42-8896-162A4439FF58Q37822174-1EEFF767-E566-4794-AECE-EF32DB172409Q37884077-0CD55EA1-FE48-41A8-A08D-FB59922693E1Q37957772-70EDA2F7-EFD5-42C2-B5CA-08175463C5E0Q38071125-A288D003-E154-4120-A3ED-3A5F26F2C822Q38213306-96902240-C5C0-4C87-B10E-618060E96590Q38383918-4F98F1BB-CAAD-4795-83F3-52A073E1A5AAQ38391306-2A6A1CE2-D8C6-4ADA-8389-8BAD918D68F6Q38401590-08CC68EB-FF59-4D24-83D6-245BB9483F88
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-2534-4160
@en
name
Joseph Friedman
@ast
Joseph Friedman
@es
Joseph Friedman
@nl
Joseph H. Friedman
@en
type
label
Joseph Friedman
@ast
Joseph Friedman
@es
Joseph Friedman
@nl
Joseph H. Friedman
@en
altLabel
Friedman J
@en
Friedman J. H.
@en
Friedman J.
@en
Friedman JH
@en
Friedman
@en
J Friedman
@en
J H Friedman
@en
J. Friedman
@en
J. H. Friedman
@en
Joseph Friedman
@en
prefLabel
Joseph Friedman
@ast
Joseph Friedman
@es
Joseph Friedman
@nl
Joseph H. Friedman
@en
P106
P21
P31
P4012
P496
0000-0003-2534-4160